StockData
Outlook Therapeutics, Inc. logo

Outlook Therapeutics, Inc. (OTLK) stock

OTLKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends September 30
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 18, 2026Score 4/30
$0.40−0.01 (-1.69%)

Close on Nov 19, 2026Market cap $97.62MP/E –Yield –

Outlook Therapeutics pe ratio

The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.

Outlook Therapeutics's pe ratio was 3.1× on Jul 31, 2025.

PE Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2025Jul 31, 20253.1×–

More Outlook Therapeutics figures

See a number that looks wrong?